Insider buying surge at Certara Inc. shows executive confidence amid a 62% YTD decline—an insider‑led potential upside, but investors should weigh the company’s high‑risk, undervalued biotech profile before buying.
Insider buying by Certara’s CCO signals confidence amid a sharp decline, offering investors a nuanced signal as the company seeks governance reforms and growth.